Medicaid prior authorization and controlled-release oxycodone

Medical Care

Volumn 46, Issue 6, 2008, Pages 573-580

  Morden, Nancy E ^a,f   Zerzan, Judy T ^b   Rue, Tessa C ^c   Heagerty, Patrick J ^c   Roughead, Elizabeth E ^d   Soumerai, Stephen B ^e   Ross Degnan, Dennis ^e   Sullivan, Sean D ^c  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Center for the Evaluative Clinical Sciences   (United States)

Author keywords

Medicaid; Pharmacy benefits; Prescription drugs; Public policy

Indexed keywords

NARCOTIC ANALGESIC AGENT; OXYCODONE;

ARTICLE; DELAYED RELEASE FORMULATION; ECONOMICS; HEALTH INSURANCE; HUMAN; MEDICAID; META ANALYSIS; ORGANIZATION AND MANAGEMENT; PATIENT REFERRAL; POLICY; PRESCRIPTION; UNITED STATES;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; GATEKEEPING; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; META-ANALYSIS AS TOPIC; ORGANIZATIONAL POLICY; OXYCODONE; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 44449116226     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31816493fb     Document Type: Article

References (36)

1. Thomson Healthcare. Red Book. Montvale, NJ: Thomson PDR; 2004.
2. IMS Health. National Prescription Audit. IMS Health; 2004.
3. Zerzan JT, Morden NE, Soumerai S, et al. Trends and geographic variation of opiate medication use in state medicaid fee-for-service programs, 1996 to 2002. Med Care. 2006;44:1005-1010.
4. Centers for Medicare and Medicaid Services. Medicaid Program Statistics Medicaid Statistical Information System (MSIS). Centers for Medicare and Medicaid Services; 2005.
5. Chou R. Drug Class Review on Long-Acting Opioid Analgesics. Final Report. Drug Effectiveness Review Project. Available at: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm.
6. U.S. Food and Drug Administration. FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc. Company Misrepresented Prescription Pain Reliever to Health Care Professionals. 2007.
7. The Associated Press. Painkiller's maker settles complaint. The New York Times. May 9, 2007.
8. National Institute for Health Care Management Research and Education Foundation. Prescription Drug Expenditures 2001: Another Year of Escalating Costs. 2002. Available at: http://www.nihcm.org/pharm.html. Accessed April 6, 2005.
9. Holahan J, Wiener JM, Lutzky AW. Health policy for low-income people: states' responses to new challenges. Health Aff (Millwood). 2002;Supp Web Exclusives:W187-W218.
10. Morden N, Sullivan S. State control of prescription drug spending: a heterogeneous approach. Health Affairs. 2005;24:1032-1038.
11. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs. 2004;23:135-146.
12. Tilly J, Elam L. Prior Authorization for Medicaid Prescription Drugs in Five States Lessons for Policy Makers. The Henry J. Kaiser Family Foundation; 2003.
13. Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry. 1985;22:396-403.
14. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
15. Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
16. Huskamp HA. Managing psychotropic drug costs: will formularies work? Health Aff (Millwood). 2003;22:84-96.
17. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351:2187-2194.
18. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;332:1612-1617.
19. Centers for Medicare and Medicaid Services. State Drug Utilization Data 2005.
20. North R. Division of Informational Analysis and Technical Assistance, Finance, Systems & Budget Group, Center for Medicaid and State Operations. In: Zerzan JT, ed., October 2006-March 2007.
21. The World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. The WHO Collaborating Centre for Drug Statistics Methodology; 2005.
22. Diggle PJ, Heagerty PJ, Liang K, et al. Analysis of Longitudinal Data. Oxford University Press; 2002.
23. Rosengart M, Cummings P, Nathens A, et al. An evaluation of state firearm regulations and homicide and suicide death rates. Inj Prev. 2005;11:77-83.
24. Cameron C, Trivedi PK. Analysis of Count Data. Cambridge University Press; 1998.
25. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356-365.
26. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
27. Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care. 1985;23:872-880.
28. Delate T, Mager DE, Sheth J, et al. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11:29-36.
29. Roughead EE, Zhang F, Ross-Degnan D, et al. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Med Care. 2006;44:378-382.
30. Davis MP, Varga J, Dickerson D, et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer. 2003;11:84-92.
31. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA. 2000;284:428-429.
32. Hamel MB, Epstein AM. Prior-authorization programs for controlling drug spending. N Engl J Med. 2004;351:2156-2158.
33. McCombs JS, Mulani P, Gibson PJ. Open access to innovative drugs: treatment substitutions or treatment expansion? Health Care Financ Rev. 2004;25:35-53.
34. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
35. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
36. Heffler S, Smith S, Keehan S, et al. Trends: U.S. health spending projections for 2004-2014. Health Aff (Millwood). 2005;Supp Web Exclusives:W5-74-W75-85.